Provided are therapies, including combination therapies, for the treatment oflung inflammation, including interstitiallung diseases (ILDs), which include the use of at least one histidyl-tRNAsynthetase (HRS) polypeptide or an expressible polynucleotidethat encodes the HRS polypeptide, alone or in combination with at least oneimmunomodulatory agent.